Credit Agricole faces a May deadline to decide whether to extend its contract with Amundi, its fund management partner, according to UniCredit CEO Andrea Orcel. Orcel recently informed investors that discussions with Credit Agricole are ongoing, as reported by Il Messaggero.
The current distribution agreement, signed in 2017 when UniCredit sold its fund business to Amundi, requires Amundi's products to account for approximately 75% of the assets UniCredit manages for Italian clients. While the contract is set to expire in 2027, UniCredit could choose not to renew it as early as this year.
Italy remains a key market for both Amundi and Credit Agricole outside France. UniCredit has proposed a 10-year extension to the contract, along with expanded geographic distribution.
Credit Agricole’s stake in Banco BPM plays a critical role in the negotiations. As Banco BPM’s largest investor, with a 15% stake and supervisory clearance to increase it to just under 20%, Credit Agricole’s decisions are pivotal. UniCredit has launched a buyout offer for Banco BPM, and Orcel expressed confidence that Credit Agricole would tender its BPM stake. The two banks reportedly held discussions over the Christmas period.
Representatives for UniCredit, Credit Agricole, and Amundi have not commented on the matter.
This decision could significantly influence partnerships and market strategies for all parties involved, particularly in the Italian market.


Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Fed Near Neutral Signals Caution Ahead, Shifting Focus to Fixed Income in 2026
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 



